The mechanism in anti-Alzheimer’s disease drugs that inhibits the production of a destructive, inflammation-causing protein in the brain has been revealed by researchers at the Hebrew university of Jerusalem. Their work, described in a recent issue of the American journal, Annals of Neurology, is likely to lead to the development of more efficient drugs than are currently in use for treating Alzheimer’s Disease as well as other neurological conditions resulting from infections, autoimmune diseases such as multiple sclerosis, or brain inflammation resulting from trauma or stroke.
